CN
时迈药业 时迈药业
For Patients, For the Unmet
We Innovate
Explore More
时迈药业 时迈药业
For Patients, For the Unmet
We Innovate
时迈药业 时迈药业
For Patients, For the Unmet
We Innovate
01
03
时迈药业
时迈药业
时迈药业
时迈药业
时迈药业
时迈药业
时迈药业
时迈药业
时迈药业
  • CentryMed
    Featured Technologies
    Explore More
    • 时迈药业
    时迈药业
    时迈药业
    时迈药业
    时迈药业
  • Targeted Activation
    Our proprietary Pro-BiTE® platform activates
    Tcells selectively within the tumor
    microenvironment (TME),
  • Safer Treatment
    significantly reducing systemic toxicity and
    unlocking safer T-cell therapies for solid
    tumors.
时迈药业
Centered Circle
Core Technologies
And Pipelines
时迈药业
Core Innovative Antibody Platform
Independently build four core platform technologies with global competitiveness
Explore More
时迈药业
Product Pipeline
Independently build four core platform technologies with global competitiveness
Explore More
Latest News
Explore More
时迈药业
Shimai Pharma Presents DNV3 (LAG-3 Antibody) Combination Therapy Results for Melanoma at ASCO 2025 Annual Meeting
June 26,2025
时迈药业
Shimai Pharma Presents SMET12 (EGFR×CD3 Bispecific Antibody) Combination Therapy Results for Advanced NSCLC at ASCO 2025 Annual Meeting
June 26,2025
时迈药业
International Endorsement, Global Leadership | GPC3×CD3 Bispecific Antibody CMD011 Receives FDA IND Clearance
June 26,2025